New product overview · November 2026

Foundation Models for MIDD

Models you can audit and trust.

Public-knowledge and proprietary foundation models for model-informed drug development: executable models, graded evidence and a configured LLM layer, delivered as one versioned package.

PK/PDPop PK/PDPBPK/PBBMQSPDisease progression
9-page product overviewNovember 2026Pricing by quote
Page one of the November 2026 IQANOVA Foundation Models for MIDD product overviewPRODUCT OVERVIEW 01 / 09

Original presentation · open or download the complete PDF.

The product, explained

One foundation model. Four connected layers.

The delivered foundation model brings together the LLM layer and the files that make its outputs traceable. A locally configured AI PC is optional.

01 / MODELS

Executable mathematics

Native models, SBML and COMBINE/OMEX packages, simulation code and a pinned execution environment. The EHMN2027 scaffold is supplied separately.

02 / FILES

Documented evidence

19 organised folders spanning evidence ledgers, calibration, verification, validation, analyses, reports, regulatory cross-references and risk registers.

03 / LLM LAYER

Traceable assistance

Configured prompts, exact run history, checksums, retrieval over project files and 22 critic checks before an evidence-backed claim is advanced.

04 / RUNTIME

Deployment that fits

Cloud-assisted, hybrid or fully local workflows. An optional AI PC can ship with an open-weight LLM and the IQANOVA runner configured and tested.

Choose your starting point

Two tiers, one evidence standard.

Timelines are targets from the agreed brief; the written quote defines exact scope, model families, licensing and price.

TIER 01

Public Knowledge

Start with public science. No confidential data required.

1–2 months
  • Built from literature, drug labels, regulatory reviews, registries and guidance
  • Questions and context of use agreed with your team
  • Frontier LLMs may be used for public-data workflows
  • Versioned outputs with explicit evidence status
Discuss Tier 1 →
TIER 02

Proprietary

Add your own protected drug and experimental information.

2–3 months
  • Includes your confidential PK/PD, in-vivo and preclinical data where agreed
  • Runs confidential workloads on a local open-weight LLM
  • Confidential content is not sent to external APIs
  • NDA and data-handling terms agreed before work begins
Discuss Tier 2 →

Both tiers are scoped deliveries; an estimated duration is not a guaranteed completion date. Local-model performance is benchmarked against frontier output before reliance, as described in the overview.

Inside every scoped package

Make the evidence visible. Keep the claims bounded.

19structured folders
22critic checks
4status axes on each file
D0–D10lifecycle diligence stages

What a reviewer can trace

Source provenance, units and rate laws, calibration and validation evidence, run history, uncertainty, applicability and explicit claim boundaries.

Datasets are distinguished as real, semi-synthetic or synthetic, with the origin of variables identified. Literature evidence is graded from A1 to E.

Questions the models can explore

Defined questions. Testable scenarios.

Examples from the November 2026 overview; each actual project needs its own context-of-use and evidence assessment.

Tier 1 · Public

First-in-human planning

For a T-cell engager class: what MABEL-based starting-dose range follows from published data, and which parameters drive it?

Tier 1 · Public

Special populations

Is an approved drug's labelled dose adjustment consistent with a mechanistic exposure prediction?

Tier 2 · Proprietary

Review your existing model

Do rate laws, units and assumptions withstand review, and which proposed claims go beyond the supporting evidence?

Deployment and maintenance

Designed to stay auditable as evidence changes.

Choose cloud-assisted public-data analysis, a hybrid mode or fully local operation for sensitive work. Every release has an evidence cut-off date, manifest and change log.

Evidence Watch, Model Maintenance and portfolio updates are optional services that start only under an activated agreement.

See deployment options in PDF ↗
Original product overview

Read all 9 pages.

Full details on package layers, tiers, example scenarios, deployment, subscriptions, expert review and ordering.

Original IQANOVA document · November 2026 · 9 pages

Cover of the original November 2026 Foundation Models for MIDD PDF
Request a scoped quote

Tell us the decision you need to make.

Send your assets, model family, questions, stage and context of use. We will respond with a written scope and price.